semaglutide for eating disorder The rapid rise of GLP-1 receptor agonists presents a complex dilemma clinicians managing patients with disorders. While these medications show potential in reducing binge eating behaviors by targeting brain reward How GLP-1 drugs may be

Recent clinical studies suggest that GLP-1 receptor agonists, including semaglutide, may offer protective benefits for liver health beyond weight loss alone

Watch doctors and researchers explain GLP-1 medications, peptide therapy, and what the latest science actually shows.

Shingles is caused by reactivation of the chickenpox virus

Amongst, overweight and obese patients defined by BMI in 2024 (58.9% [95% CIs 53.3-64.2%] female [182/309], median [IQR] age 56.6 [46.2-66.1]) GLP 1RA use has increased from 3.2% (10/309 [95% CIs 1.8-5.9%]) to 13.6% (42/309 [95% CIs 10.2-17.9%] [p=7.1x10-6])

Emerging research, treatment potential, survival impact, and what it means for future cancer therapy.